Eli Lilly's Kisunla approved in China for Alzheimer's treatment, showing positive results

From Investing.com: 2024-12-17 21:00:28

China approves Eli Lilly’s Kisunla for early Alzheimer’s, joining US, Japan, and UK. Kisunla, like Leqembi, clears beta-amyloid. In trials, Kisunla slowed memory decline by 29%. Brain swelling and bleeding were side effects, but mostly mild. FDA warns of risks, but gradual dosing can reduce serious side effects.

Kisunla has finite dosing, unlike Leqembi, allowing patients to stop when amyloid plaques disappear. EU is reviewing Kisunla after rejecting Leqembi. Alzheimer’s accounts for 60%-70% of dementia cases, says WHO. Patients now have another option for treating early Alzheimer’s with Kisunla’s approval in China.



Read more at Investing.com: Eli Lilly’s Alzheimer’s treatment approved in China By Reuters